[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 788,466
  • Shares Outstanding, K 99,303
  • Annual Sales, $ 84,280 K
  • Annual Income, $ -171,300 K
  • EBIT $ -202 M
  • EBITDA $ -207 M
  • 60-Month Beta 0.95
  • Price/Sales 9.28
  • Price/Cash Flow N/A
  • Price/Book 12.76

Options Overview Details

View History
  • Implied Volatility 102.63% (+5.61%)
  • Historical Volatility 101.18%
  • IV Percentile 50%
  • IV Rank 18.21%
  • IV High 341.30% on 03/30/26
  • IV Low 49.51% on 07/11/25
  • Expected Move (DTE 6) 0.47 (5.89%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,626
  • Volume Avg (30-Day) 404
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 7,797
  • Open Int (30-Day) 9,127
  • Expected Range 7.47 to 8.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 2
  • High Estimate $-0.49
  • Low Estimate $-0.61
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) -19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.49 +6.01%
on 07/08/26
10.87 -26.95%
on 06/24/26
-1.32 (-14.25%)
since 06/10/26
3-Month
7.03 +12.94%
on 05/15/26
10.87 -26.95%
on 06/24/26
-0.11 (-1.37%)
since 04/10/26
52-Week
6.66 +19.22%
on 11/21/25
18.63 -57.38%
on 07/28/25
-10.04 (-55.84%)
since 07/10/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY).  Such investors are advised...

SPRY : 7.94 (+0.76%)
ARS Pharmaceuticals Announces CEO Succession

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of  Leadership Since Co-Founding the Company Donn Casale, President, Appointed Chief Executive Officer and...

SPRY : 7.94 (+0.76%)
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky

ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contradicted...

SPRY : 7.94 (+0.76%)
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud

ARS Pharmaceuticals guided investors toward broad commercial coverage of Neffy, including the achievement of approximately 80% coverage -- the July 2026 payer cycle delivered zero new formulary additions,...

SPRY : 7.94 (+0.76%)
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals CEO projected CVS Caremark formulary inclusion was expected for the July 1, 2026 commercial formulary cycle -- the July 2026 payer cycle produced zero new formulary additions, and SPRY...

SPRY : 7.94 (+0.76%)
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”)...

SPRY : 7.94 (+0.76%)
ARS Pharmaceuticals Provides Commercial and Financial Updates

No new commercial formulary additions or coverage decisions issued for  neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion...

SPRY : 7.94 (+0.76%)
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully Collaboration focuses on education...

SPRY : 7.94 (+0.76%)
Canadian CPI Featured in Short Week

Monday U.S. Featured Earnings Baidu Inc (NASDAQ:BIDU) (Q1) EPS of $1.50, compared to ...

NVDA : 210.96 (+4.03%)
DE : 586.86 (-1.02%)
BEKE : 15.57 (+2.10%)
SPRY : 7.94 (+0.76%)
TJX : 151.34 (+0.29%)
ADI : 395.65 (+0.51%)
BIDU : 117.53 (+0.02%)
TCOM : 42.80 (+3.31%)
MUFG : 21.65 (+1.88%)
KEYS : 322.05 (-0.04%)
HTHT : 41.11 (+0.39%)
HD : 343.30 (+1.35%)
ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy,...

SPRY : 7.94 (+0.76%)

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 8.52
2nd Resistance Point 8.29
1st Resistance Point 8.12
Last Price 7.94
1st Support Level 7.72
2nd Support Level 7.49
3rd Support Level 7.32

See More

52-Week High 18.63
Fibonacci 61.8% 14.06
Fibonacci 50% 12.64
Fibonacci 38.2% 11.23
Last Price 7.94
52-Week Low 6.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.